- $36.71bn
- $43.10bn
- $9.89bn
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova
Biogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen Inc. reports results for the quarter ended September 30 - Earnings Summary
Biogen Q3 revenue beats on Apellis acquisition, product demand
Brief: Biogen Q3 Adjusted EPS USD 2.62 Vs. IBES Estimate USD 1.99
Brief: Biogen Expects Total Rev To Increase By A Mid-Single Digit Percentage For 2026
Biogen beats third-quarter results on strength in rare disease drugs
US RESEARCH ROUNDUP-Coca-Cola, Ecolab, Visa
Brief: Biogen Canada Provides Update on Draft Recommendation Supporting Expanded SPINRAZA Reimbursement for SMA
US STOCKS ON THE MOVE-Microsoft, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Microsoft, C3.ai, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences
U.S. STOCKS ON THE MOVE-GoDaddy, Biogen, IREN
J.P. Morgan upgrades Biogen to 'overweight', shares rise
US RESEARCH ROUNDUP-Biogen, Datadog, Tesla
U.S. STOCKS ON THE MOVE -VF Corp, Biogen, AbbVie